NASDAQ:BLPH - Bellerophon Therapeutics Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.64 +0.05 (+8.47 %) (As of 05/24/2019 04:00 PM ET)Previous Close$0.59Today's Range$0.59 - $0.6452-Week Range$0.47 - $3.30Volume431,337 shsAverage Volume349,972 shsMarket Capitalization$44.10 millionP/E RatioN/ADividend YieldN/ABeta-0.02 ProfileAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Bellerophon Therapeutics, Inc. is a clinical-stage therapeutics company, which focuses on developing innovative products at the intersection of drugs and devices that address significant unmet medical needs in the treatment of cardiopulmonary diseases. The company engages in two programs including INOpulse and BCM. INOpulse is based on proprietary pulsatile nitric oxide delivery device. BCM is based on placebo-controlled clinical trial designed to support CE mark registration in the European Union. Bellerophon Therapeutics was founded in 2009 and is headquartered in Warren, NJ. Receive BLPH News and Ratings via Email Sign-up to receive the latest news and ratings for BLPH and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BLPH Previous Symbol CUSIPN/A CIK1600132 Webhttp://www.bellerophon.com/ Phone908-574-4770Debt Debt-to-Equity Ratio0.18 Current Ratio2.99 Quick Ratio2.99Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash Flow$0.0476 per share Price / Cash Flow13.45 Book Value$0.15 per share Price / Book4.27Profitability EPS (Most Recent Fiscal Year)($0.34) Net Income$2.81 million Net MarginsN/A Return on Equity674.04% Return on Assets71.94%Miscellaneous Employees17 Outstanding Shares68,907,000Market Cap$44.10 million Next Earnings Date8/7/2019 (Estimated) OptionableNot Optionable Bellerophon Therapeutics (NASDAQ:BLPH) Frequently Asked Questions What is Bellerophon Therapeutics' stock symbol? Bellerophon Therapeutics trades on the NASDAQ under the ticker symbol "BLPH." How were Bellerophon Therapeutics' earnings last quarter? Bellerophon Therapeutics Inc (NASDAQ:BLPH) issued its quarterly earnings data on Thursday, May, 9th. The biotechnology company reported $0.01 earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.11. View Bellerophon Therapeutics' Earnings History. When is Bellerophon Therapeutics' next earnings date? Bellerophon Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August 7th 2019. View Earnings Estimates for Bellerophon Therapeutics. What price target have analysts set for BLPH? 2 analysts have issued 12-month price objectives for Bellerophon Therapeutics' shares. Their forecasts range from $3.00 to $3.00. On average, they expect Bellerophon Therapeutics' stock price to reach $3.00 in the next twelve months. This suggests a possible upside of 368.8% from the stock's current price. View Analyst Price Targets for Bellerophon Therapeutics. What is the consensus analysts' recommendation for Bellerophon Therapeutics? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bellerophon Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Bellerophon Therapeutics. What are Wall Street analysts saying about Bellerophon Therapeutics stock? Here are some recent quotes from research analysts about Bellerophon Therapeutics stock: 1. According to Zacks Investment Research, "Bellerophon Therapeutics LLC is a biotherapeutics company. It is focused on developing products for the treatment of cardiopulmonary and cardiac diseases. The company's product pipeline consists of INOpulse and BCM which are in different clinical stage. Bellerophon Therapeutics LLC is based in Hampton, New Jersey. " (5/15/2019) 2. HC Wainwright analysts commented, "Valuation and Risks. Our price target of $3/share is based on a discounted cash flow analysis (2018-2026) using a 12% discount rate and 2% growth rate, in line with the expected discount and growth parameters of a development-stage drug company. Risks to our investment thesis and target price include: (1) failure in clinical studies; (2) failure to secure regulatory approval; and (3) smaller than anticipated commercial opportunity due to market size, competition and pricing." (1/29/2019) 3. Maxim Group analysts commented, "We are initiating coverage of $3 price target. Bellerophon’s lead product is the INOpulse delivery system of inhaled nitric oxide (iNO) for the outpatient management of pulmonary hypertension (PH) in chronic pulmonary diseases." (1/24/2019) Has Bellerophon Therapeutics been receiving favorable news coverage? News articles about BLPH stock have trended negative this week, InfoTrie reports. InfoTrie identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Bellerophon Therapeutics earned a media sentiment score of -2.9 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an effect on the stock's share price in the next several days. Who are some of Bellerophon Therapeutics' key competitors? Some companies that are related to Bellerophon Therapeutics include BioXcel Therapeutics (BTAI), Checkpoint Therapeutics (CKPT), Strongbridge Biopharma (SBBP), Sol Gel Technologies (SLGL), Trevi Therapeutics (TRVI), LifeVantage (LFVN), XOMA (XOMA), Harrow Health (HROW), Sesen Bio (SESN), Tyme Technologies (TYME), Galmed Pharmaceuticals (GLMD), Eton Pharmaceuticals (ETON), Adamas Pharmaceuticals (ADMS), Mustang Bio (MBIO) and Provention Bio (PRVB). What other stocks do shareholders of Bellerophon Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Bellerophon Therapeutics investors own include Corbus Pharmaceuticals (CRBP), AVEO Pharmaceuticals (AVEO), Aurinia Pharmaceuticals (AUPH), Synergy Pharmaceuticals (SGYP), BIOLINERX LTD/S (BLRX), CytRx (CYTR), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX) and Cara Therapeutics (CARA). Who are Bellerophon Therapeutics' key executives? Bellerophon Therapeutics' management team includes the folowing people: Fabian Tenenbaum, Chief Executive Officer & DirectorAssaf Korner, Chief Financial Officer & SecretaryAmy Edmonds, VP-Clinical Operations & AdministrationMartin Dekker, Vice President-Engineering & ManufacturingPeter Fernandes, Chief Regulatory & Safety Officer When did Bellerophon Therapeutics IPO? (BLPH) raised $60 million in an IPO on Friday, February 13th 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. Leerink Partners and Cowen and Company served as the underwriters for the IPO and FBR and SunTrust Robinson Humphrey were co-managers. Who are Bellerophon Therapeutics' major shareholders? Bellerophon Therapeutics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Renaissance Technologies LLC (1.91%), Arch Venture Corp (1.40%) and Sabby Management LLC (0.45%). Company insiders that own Bellerophon Therapeutics stock include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock and Naseem Amin. View Institutional Ownership Trends for Bellerophon Therapeutics. Which major investors are buying Bellerophon Therapeutics stock? BLPH stock was acquired by a variety of institutional investors in the last quarter, including Arch Venture Corp, Sabby Management LLC and Renaissance Technologies LLC. Company insiders that have bought Bellerophon Therapeutics stock in the last two years include Associates Iv L P Venrock, Fabian Tenenbaum, Jonathan M Peacock and Naseem Amin. View Insider Buying and Selling for Bellerophon Therapeutics. How do I buy shares of Bellerophon Therapeutics? Shares of BLPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Bellerophon Therapeutics' stock price today? One share of BLPH stock can currently be purchased for approximately $0.64. How big of a company is Bellerophon Therapeutics? Bellerophon Therapeutics has a market capitalization of $44.10 million. The biotechnology company earns $2.81 million in net income (profit) each year or ($0.34) on an earnings per share basis. Bellerophon Therapeutics employs 17 workers across the globe. What is Bellerophon Therapeutics' official website? The official website for Bellerophon Therapeutics is http://www.bellerophon.com/. How can I contact Bellerophon Therapeutics? Bellerophon Therapeutics' mailing address is 184 LIBERTY CORNER ROAD SUITE 302, WARREN NJ, 07059. The biotechnology company can be reached via phone at 908-574-4770 or via email at [email protected] MarketBeat Community Rating for Bellerophon Therapeutics (NASDAQ BLPH)Community Ranking: 2.9 out of 5 ( )Outperform Votes: 243 (Vote Outperform)Underperform Votes: 173 (Vote Underperform)Total Votes: 416MarketBeat's community ratings are surveys of what our community members think about Bellerophon Therapeutics and other stocks. Vote "Outperform" if you believe BLPH will outperform the S&P 500 over the long term. Vote "Underperform" if you believe BLPH will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 5/24/2019 by MarketBeat.com StaffFeatured Article: What is a Futures Contract? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.